The Canadian Centre for Applied Research in Cancer Control

Patient perspectives of Value Frameworks used to Guide Oncology Treatment Decisions

/0 Comments/in /by
Lead Researcher(s):  Winson Cheung & Colleen Cuthbert Lead Institution: University of Calgary Co-Investigators:  ARCC Program Area(s): Societal Values and Public Engagement Funding Term: 2021-2022 Project Summary: Value assessment frameworks have been developed to guide decision making about oncology treatments. The goal of these frameworks is to objectively delineate the value (more…)
The Canadian Centre for Applied Research in Cancer Control

Understanding British Columbia cancer patients’ experiences with virtual health before and during the COVID-19 pandemic

/0 Comments/in /by
Lead Researcher(s):  Stuart Peacock Lead Institution: BC Cancer Co-Investigators: Helen McTaggart-Cowan, Lena Cuthbertson, Sara Izadi-Najabadi, Leah Lambert, Craig Mitton ARCC Program Area(s): Survivorship Funding Term: 2021-2022 Project Summary: The COVID-19 pandemic has impacted cancer patients in British Columbia in receiving their care in a timely fashion. Many cancer patients have (more…)
The Canadian Centre for Applied Research in Cancer Control

Benchmarking End of Life Quality Indicators by Tumor Type & Describing models of palliative care across Canada

/0 Comments/in /by
Lead Researcher(s): Aynharan Sinnarajah Lead Institution: University of Calgary Co-Investigators: Lisa Barbera, Hsien Seow, Peter Tanuseputro, Leonie Herx ARCC Program Area(s): Health Systems, Services, and Policy Funding Term: 2021-2022 Project Summary: Problem: The quality of end-of-life (EOL) cancer care is variable across the country. Previous work has looked at EOL (more…)
The Canadian Centre for Applied Research in Cancer Control

Evaluation of the systemic cancer therapy volume-outcome association: a population-based study to inform the optimal provincial organization and delivery of systemic cancer therapy

/0 Comments/in /by
Lead Researcher(s):  Michael J. Raphael Lead Institution: Sunnybrook Research Institute Co-Investigators:Peter Austin, Christopher Booth, Katherine Enright, Craig Earle, Natalie Coburn, Julie Hallet, Antoine Eskander, Joseph Del Paggio ARCC Program Area(s): Health Systems, Services, and Policy Funding Term: 2021-2022 Project Summary: There is strong evidence in the surgical oncology literature to (more…)
The Canadian Centre for Applied Research in Cancer Control

Childhood cancer drug funding in Ontario: A citizen panel approach to identifying public priorities

/0 Comments/in /by
Lead Researcher(s):  Avram Denburg Lead Institution: The Hospital for Sick Children Co-Investigators: Abelson J, Bombard Y, Croker A, Fraser B, Gauvreau C, Gibson J, Hayeems R, Moore-Hepburn C, Palmer A, Wilson  M ARCC Program Area(s): Societal Values and Public Engagement Funding Term: 2020-2022 Project Summary: Health systems are faced with (more…)
The Canadian Centre for Applied Research in Cancer Control

Individuals’ preferences for using cannabis as a complementary therapy for managing cancer-related symptoms

/0 Comments/in /by
Lead Researcher(s): Helen McTaggart-Cowan Lead Institution: BC Cancer Co-Investigators: Colene Bentley, Philippa Hawley, Sara Izadi-Najabadi, Adam Raymakers, Stuart Peacock ARCC Program Area(s): Societal Values and Public Engagement Funding Term: 2019-2021 Project Summary: Value assessment frameworks have been developed to guide decision making about oncology treatments. The goal of these frameworks (more…)
The Canadian Centre for Applied Research in Cancer Control

A qualitative evaluation of patient engagement in the pan-Canadian Oncology Drug Review process – Part 2: Patient group perspectives

/0 Comments/in /by
Lead Investigator(s): Kelvin Chan Lead Institution: Sunnybrook Research Institute Co-Investigators: Alexandra Chambers, Helen Mai, Linda Rozmovits ARCC Program Area(s): Health Technology Assessment Funding Term: 2017-2018 Patient input into drug funding reviews by Health Technology Assessment (HTA) agencies is essential to ensuring that patient perspectives inform decision-making about drug reimbursement in (more…)